A Multi-center, Open Label, Phase III Study to Evaluate the Efficacy and Safety of MIL62 Plus Lenalidomide Versus Lenalidomide in Subjects With Follicular Lymphoma Refractory to Rituximab
Latest Information Update: 22 Jul 2024
At a glance
- Drugs MIL-62 (Primary) ; Lenalidomide
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Sponsors Beijing Mabworks Biotech
- 09 Aug 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Mar 2024.
- 13 Feb 2022 Status changed from not yet recruiting to recruiting.
- 08 Apr 2021 New trial record